On October 24, 2023 Akeso reported poster presentation at the 2023 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress from its cadonilimab ( PD-1/CTLA-4 bispecific antibody) combined with lenvatinib for first-line treatment of Advanced Hepatocellular Carcinoma (HCC) (Press release, Akeso Biopharma, OCT 24, 2023, View Source [SID1234636308]). The principal investigators of the study are Prof. Bai Li and Prof. Jiao Shunchang of the Chinese PLA General Hospital.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The results indicated that the novel combination therapy of PD-1/CTLA-4 bispecific antibody plus lenvatinib demonstrated promising efficacy and manageable toxicity that could provide an option of treatment in first-line treatment of advanced HCC. At the 2021 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, Akeso presented the preliminary therapeutic effect of cadonilimab combined with lenvatinib for first-line therapy of advanced HCC, showing promising anti-tumor activity and improved tolerability. The 2 years median follow-up results presented at the 2023 ESMO (Free ESMO Whitepaper) meeting further emphasized the efficacy of cadonilimab in improving overall survival (OS) among advanced patients.
Data Highlights:
Results demonstrated the outstanding efficacy of cadonilimab when combined with lenvatinib as a first-line treatment for HCC. The preliminary efficacy data outperformed those of approved therapies. As of July 28, 2023, the median follow-up period was 27.4 months.
When cadonilimab was dosed at 6 mg/kg Q2W, the objective response rate (ORR) was 35.5%, the median duration of response (mDoR) was 13.6 months, the median progression free survival (mPFS) was 8.61 months, and mOS was 27.1 months.
When the dose of cadonilimab was 15 mg/kg Q3W, the ORR was 35.7%, the mDoR was 13.7 months, the mPFS was 9.82 months, and the mOS was not yet reached.
The mPFS for first-line HCC treatment with the combination of cadonilimab and lenvatinib was higher compared to approved therapies. The study indicated that the improvement in PFS was more significant with the higher dose of cadonilimab (8.6 months at 6 mg/kg every 2 weeks vs. 9.8 months at 15 mg/kg every 3 weeks).
The adverse effects of the combination of cadonilimab and lenvatinib at all dosage levels were readily manageable without any new safety signals or cadonilimab-associated fatalities.
Akeso is currently conducting a randomized, double-blind, controlled Phase III clinical trial (AK104-306, NCT05489289) to evaluate the efficacy and safety of cadonilimab as adjuvant therapy for high-risk hepatocellular carcinoma after curative resection. The potential efficacy of cadonilimab for both operable and advanced HCC holds great promise for improving long-term survival rates for the entire HCC population.
About Cadonilimab(PD-1/CTLA-4 bispecific antibody)
Cadonilimab is a first-in-class bispecific antibody that targets both PD-1 and CTLA-4 developed by Akeso. It is a symmetric tetravalent bispecific antibody with a crystallizable fragment (Fc)-null design. In addition to demonstrating biological activity similar to that of the combination of CTLA-4 and PD-1 antibodies, cadonilimab possesses higher binding avidity in a high-density PD-1 and CTLA-4 setting than in a low-density PD-1 setting, while a mono-specific anti-PD-1 antibody does not demonstrate this differential activity. With no binding to Fc receptors, cadonilimab shows minimal antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and interleukin-6 (IL-6)/IL-8 release. These features all likely contribute to significantly lower toxicities of cadonilimab observed in the clinic. Higher binding avidity of cadonilimab in a tumor-like setting and Fc-null design may lead to better drug retention in tumors and contribute to better safety while achieving anti-tumor efficacy.
Cadonilimab has been approved by the China National Medical Products Administration for recurrent or metastatic cervical cancer. Cadonilimab has been included and recommended in multiple clinical guidelines such as CSCO. In its first 12 months on the market, cadonilimab generated impressive sales revenue of 1.15 billion RMB. Cadonilimab has been engaged in more than 60 ongoing clinical trials including investigator-initiated studies. Patient enrollment has been completed for the phase 3 study of cadonilimab for first-line treatment of advanced cervical cancer as well as a phase 3 study of cadonilimab in combination with chemotherapy as first-line therapy in gastric cancer. A phase 3 study of cadonilimab as an adjuvant treatment for hepatocellular carcinoma is ongoing. Furthermore, a Phase 3 study comparing cadonilimab with chemotherapy to tislelizumab Injection with chemotherapy is underway for the first-line treatment of PD-L1 expression-negative non-small cell lung cancer.